Meseci, ElifNaki, Mehmet Murat2023-02-212023-02-212019-01-0110.4274/jtgga.galenos.2019.2019.0061https://hdl.handle.net/11443/1193http://dx.doi.org/10.4274/jtgga.galenos.2019.2019.0061Objective: To determine the clinical and pathologic characteristics, prognostic factors, surgical practice, adjuvant therapies, and survival outcomes of patients with uterine sarcoma diagnosed and treated in our institution. Material and Methods: Patients diagnosed and treated for uterine sarcomas at our institution from 2009 to 2017 were retrospectively evaluated. All histologic slides from the specimens underwent a thorough pathologic review by a gynecologic pathologist. The following variables were assessed: age, family history of cancer, smoking status, age of menarche, parity, age at first delivery, related symptoms, clinical staging, histologic type, treatment received, disease-free period, and the time and site of recurrence, as well as treatment of the latter and overall survival. Results: Ten patients were diagnosed as having leiomyosarcoma, a further 10 patients had malignant mixed mullerian tumors, and five had endometrial stromal sarcomathe remaining nine patients had other tumors. At the end of our study, 12 (35.3\%) patients were alive and in remission, four (11.8\%) were alive with disease, 10 (29.4\%) were lost to follow-up, and eight (23.5\%) had died. The mean survival time was 80.92 months, and the 2-year survival rate was 75.6\%. We found that survival was significantly shorter in the presence of lymph node involvement, residual tumor, and recurrence. Conclusion: This study serves to inform physicians about the outcome of various uterine sarcomas that were diagnosed and managed at our center. We found that 35.3\% of our patients were alive and in remission, 11.8\% were alive with disease, 29.4\% were lost to follow-up, and 23.5\% of patients died.CarcinosarcomaleiomyosarcomaprognosissarcomasurvivalArticleWOS:000483978800006